Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy

Figure 3

Recurrence-free survival (RFS) according to treatment in patients with stage II and stage III colorectal cancers. (A) Kaplan-Meier curves for the RFS of patients with stage II CpG island methylation phenotype (CIMP)-low/negative CRCs. (B) Kaplan-Meier curves for the RFS of patients with stage II CIMP-high CRCs. (C) Kaplan-Meier curves for the RFS of patients with stage III CIMP-low/negative CRCs. (D) Kaplan-Meier curves for the RFS of patients with stage III CIMP-high CRCs.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us